Developer docs
API playgroundTry for free, no card

Search company profiles

Fisher Wallace Laboratories

Full company profile

uuid0002iax

Namestring
Fisher Wallace Laboratories
Legal namestring
Fisher Wallace Laboratories, Inc.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Fisher Wallace Laboratories, Inc. is a privately held Brooklyn, New York–based medical device company (founded 2009; 1-10 employees) that develops and sells prescription wearable brain stimulation devices for treating neuropsychiatric conditions including anxiety, depression, insomnia, bipolar II depression, and symptoms of Parkinson's disease. Its core technology is transcranial alternating current stimulation (tACS), a non-invasive modality that entrains neural oscillations and induces synaptic plasticity; nearly 2,000 participants have been enrolled across the company's clinical studies, and Harvard Medical School / Massachusetts General Hospital researchers have modeled the technology's engagement of brain structures governing mood, sleep, autonomic function, and cognitive resilience.

The company's commercial product base consists of the FDA-cleared Version 1.0 proof-of-concept device (over 70,000 units sold since 2010, distributed through thousands of prescribers) plus a line of replacement accessories (sponges, headbands, lead wires, receptacles, carrying case). Its next-generation OAK device — developed in collaboration with the team behind Beats and Nest and designed for population-scale deployment — anticipates initial FDA clearance for anxiety in Q3 2026 and additional indications (insomnia, depression, human performance) in 2027, with a first manufacturing run of 10,000 units. The OAK device is currently being pilot tested within the U.S. Department of Veterans Affairs.

Fisher Wallace generates revenue primarily through direct-to-consumer e-commerce sales of its prescription device and accessories on fisherwallace.com, and it has been a notable user of SEC-regulated equity crowdfunding — having raised more than $11 million from early adopters via StartEngine and its own platform — with an institutional $2.5 million round led by SHUFL Capital in April 2022. Key customer segments include individual patients with neuropsychiatric conditions, first responders (evidenced by a 164-participant study with the Seattle Police Department and Washington State University), and military veterans (via the VA pilot), supported by an advisory bench drawn from Mass General Brigham, Harvard Medical School, and former VA leadership.

Short descriptiontext

Fisher Wallace Laboratories is a privately held Brooklyn-based medical device company selling prescription wearable transcranial alternating current stimulation (tACS) devices for anxiety, depression, and insomnia, with a next-generation population-scale OAK device pending FDA clearance in Q3 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBrooklyn, United States
HQ citystring
Brooklyn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable brain stimulation, cranial electrotherapy devices, transcranial current stimulation, prescription neurostimulation, mental health devices
Industry3 codes
PRIMARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYCRACAIAG
Sleep Tech Wearables
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Wearable Neurostimulation Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Prescription Wearable Device Sales
TypeHardware Sales
Description

Sale of FDA-cleared brain stimulation devices directly to patients with prescriptions. The company has sold over 70,000 units of its proof-of-concept device.

fisherwallace.com
2Accessories and Consumables
TypeHardware Sales
Description

Sale of replacement accessories including sponges, headbands, lead wires, and carrying cases for the Version 1.0 device.

fisherwallace.com
3Equity Crowdfunding
TypeOne Time License
Description

SEC-regulated equity crowdfunding campaigns raising capital from early adopters and retail investors. Over $11 million raised collectively through these campaigns.

fisherwallace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1Accessories and replacement parts for Version 1.0 device
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Extra Fisher Wallace Sponges (48 pack): $15; Replacement Velcro Headband: $14; Replacement Black Lead Wire: $24; Replacement Red Lead Wire: $24; Replacement Sponge Receptacles: $24; Fisher Wallace Pouch: $15

fisherwallace.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1OAK
Description

Next-generation prescription brain stimulation device designed for population-scale, the result of 17 years of clinical research and product development in collaboration with the team behind Beats and Nest. Anticipated initial FDA clearance for anxiety treatment in Q3 2026.

fisherwallace.com
+1 more record
Core offering1 text field

Fisher Wallace Laboratories designs, manufactures, and sells prescription wearable brain stimulation devices using Transcranial Alternating Current Stimulation (tACS) for the treatment of anxiety, depression, and insomnia. Its currently commercial device, Version 1.0, is FDA-cleared, with over 70,000 units sold; the next-generation OAK device is in development pending initial FDA clearance anticipated in Q3 2026. The company also sells replacement accessories — sponges, headbands, lead wires, receptacles, and carrying cases — to support its installed base.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Rapid anxiety symptom reduction that continued improving over eight-week study period in 164 first responders
+3 more records
Product overview1 text field

Fisher Wallace Laboratories offers prescription wearable brain stimulation devices for treating neuropsychiatric disorders. The portfolio consists of two main products: the original Version 1.0 proof-of-concept device (FDA-cleared for anxiety, depression, and insomnia, with over 70,000 units sold since 2010) and the next-generation OAK device (anticipating FDA clearance in Q3 2026). Both products use Transcranial Alternating Current Stimulation (tACS) technology. The product line is supported by a range of accessories including replacement sponges, headbands, lead wires, electrode receptacles, and carrying cases.

Product and service8 records
1OAK Brain Stimulation Device
CategoryPrescription brain stimulation device
Description

Prescription wearable brain stimulation device using Transcranial Alternating Current Stimulation (tACS) to treat anxiety at population scale, with anticipated FDA clearance for anxiety in Q3 2026 and follow-on indications for insomnia, depression, and human performance in 2027.

2Fisher Wallace Version 1.0 Brain Stimulation Device
CategoryPrescription brain stimulation device
Description

FDA-cleared wearable brain stimulation device using Transcranial Alternating Current Stimulation (tACS) to treat anxiety, depression, and insomnia in adults, distributed to more than 70,000 patients through a prescriber channel.

3Extra Fisher Wallace Sponges (48 pack)
CategoryDevice accessory / consumable
Description

Replacement electrode sponges packaged in a 48-count supply (approximately 6 months) intended for Version 1.0 device users, with recommended replacement every two weeks.

4Replacement Velcro Headband
CategoryDevice accessory
Description

Adjustable replacement Velcro headband used to secure electrode placement during Version 1.0 brain stimulation treatment sessions.

5Replacement Black Lead Wire
CategoryDevice accessory
Description

Replacement black lead wire that connects the Version 1.0 brain stimulation device to the headband electrodes.

6Replacement Red Lead Wire
CategoryDevice accessory
Description

Replacement red lead wire that connects the Version 1.0 brain stimulation device to the headband electrodes.

7Replacement Sponge Receptacles
CategoryDevice accessory
Description

Replacement electrode receptacles that hold sponges on the Version 1.0 brain stimulation device during treatment sessions.

8Fisher Wallace Pouch
CategoryDevice accessory
Description

Carry case designed for storing and transporting the Fisher Wallace brain stimulation device and its accessories.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Harvard Medical School
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Researchers at Harvard Medical School modeled the strength of the company's neurostimulation in the brain, demonstrating significant engagement of structures governing mood, sleep, autonomic function, and cognitive resilience in 2025 research.

fisherwallace.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborated with Fisher Wallace on clinical research demonstrating device effectiveness and safety. Home to key advisor Maurizio Fava, MD, Chair of Department of Psychiatry at Mass General Brigham.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Company's next-generation technology OAK is currently being pilot tested in the U.S. Department of Veterans Affairs. Advisory board includes Ninth Secretary of Veterans Affairs David Shulkin.

4Seattle Police Department
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated in real-world study of 164 first responders demonstrating rapid anxiety symptom reduction over eight-week study period as part of FDA clearance application.

fisherwallace.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered with company and other first responder organizations for the clinical study supporting FDA clearance application.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
1Alpha-Stim (Electromedical Products)
TypeDirect peer
Description

Alpha-Stim manufactures FDA-cleared cranial electrotherapy stimulation (CES) devices for anxiety, insomnia, and depression. It is the most direct competitor to Fisher Wallace in non-invasive electrotherapeutic brain stimulation for mental health, serving overlapping patient populations and prescriber channels.

TypeDirect peer
Description

Neuronetics markets NeuroStar, a transcranial magnetic stimulation (TMS) system for major depressive disorder. It competes for the same prescriber relationships and depression patient population as Fisher Wallace, offering an alternative non-invasive brain stimulation modality.

TypeDirect peer
Description

Brainsway develops deep transcranial magnetic stimulation (Deep TMS) systems for depression, OCD, and other psychiatric conditions. It is a comparable non-pharmaceutical, non-invasive neuromodulation company serving similar patient populations and prescriber markets as Fisher Wallace.

TypeDirect peer
Description

NeuroSigma markets the Monarch eTNS system, a non-invasive external trigeminal nerve stimulation device cleared by FDA for ADHD and depression. It is a direct competitor in the prescription non-invasive brain stimulation category targeting neuropsychiatric conditions.

5Magstim
TypeBroad incumbent
Description

Magstim is an established manufacturer of TMS stimulators and coils used in clinical research and depression treatment. It serves the same transcranial stimulation clinical and research market as Fisher Wallace, with a broader neurology-focused product portfolio.

6Apollo Neuroscience
TypeEmerging player
Description

Apollo Neuroscience offers a consumer wearable that delivers gentle vibrations to influence the nervous system for stress, sleep, and focus. While it uses a different mechanism (vibrotactile vs. electrical stimulation), it competes for the same mental wellness consumer and prescriber attention.

TypeEmerging player
Description

Halo Neuroscience developed transcranial direct current stimulation (tDCS) headbands initially for athletic performance. It is an emerging non-invasive neurostimulation company with overlapping technology category (electrical brain stimulation) and partial overlap in mental performance applications.

TypeEmerging player
Description

Cerebral is a tele-mental-health company prescribing and managing treatment for anxiety, depression, and insomnia. It represents a partial overlap through shared patient population and prescriber relationships, though Cerebral focuses on pharmaceutical rather than device-based treatment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fisher Wallace Laboratories

Wearable Neurostimulation Devicesfisherwallace.com

Fisher Wallace Laboratories is a privately held Brooklyn-based medical device company selling prescription wearable transcranial alternating current stimulation (tACS) devices for anxiety, depression, and insomnia, with a next-generation population-scale OAK device pending FDA clearance in Q3 2026.

What Fisher Wallace Laboratories does

Fisher Wallace Laboratories, Inc. is a privately held Brooklyn, New York–based medical device company (founded 2009; 1-10 employees) that develops and sells prescription wearable brain stimulation devices for treating neuropsychiatric conditions including anxiety, depression, insomnia, bipolar II depression, and symptoms of Parkinson's disease. Its core technology is transcranial alternating current stimulation (tACS), a non-invasive modality that entrains neural oscillations and induces synaptic plasticity; nearly 2,000 participants have been enrolled across the company's clinical studies, and Harvard Medical School / Massachusetts General Hospital researchers have modeled the technology's engagement of brain structures governing mood, sleep, autonomic function, and cognitive resilience.

The company's commercial product base consists of the FDA-cleared Version 1.0 proof-of-concept device (over 70,000 units sold since 2010, distributed through thousands of prescribers) plus a line of replacement accessories (sponges, headbands, lead wires, receptacles, carrying case). Its next-generation OAK device — developed in collaboration with the team behind Beats and Nest and designed for population-scale deployment — anticipates initial FDA clearance for anxiety in Q3 2026 and additional indications (insomnia, depression, human performance) in 2027, with a first manufacturing run of 10,000 units. The OAK device is currently being pilot tested within the U.S. Department of Veterans Affairs.

Fisher Wallace generates revenue primarily through direct-to-consumer e-commerce sales of its prescription device and accessories on fisherwallace.com, and it has been a notable user of SEC-regulated equity crowdfunding — having raised more than $11 million from early adopters via StartEngine and its own platform — with an institutional $2.5 million round led by SHUFL Capital in April 2022. Key customer segments include individual patients with neuropsychiatric conditions, first responders (evidenced by a 164-participant study with the Seattle Police Department and Washington State University), and military veterans (via the VA pilot), supported by an advisory bench drawn from Mass General Brigham, Harvard Medical School, and former VA leadership.

Fisher Wallace Laboratories firmographics

Firmographics
Name
Fisher Wallace Laboratories
Legal name
Fisher Wallace Laboratories, Inc.
Website
https://fisherwallace.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Fisher Wallace Laboratories is a privately held Brooklyn-based medical device company selling prescription wearable transcranial alternating current stimulation (tACS) devices for anxiety, depression, and insomnia, with a next-generation population-scale OAK device pending FDA clearance in Q3 2026.
Ownership category
akta.pro rank

Fisher Wallace Laboratories industry classification

Industry
Product category
Wearable Neurostimulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYCRACAIAG
Sleep Tech Wearables
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Wearable brain stimulation
  • Cranial electrotherapy devices
  • Transcranial current stimulation
  • Prescription neurostimulation
  • Mental health devices

Where Fisher Wallace Laboratories is headquartered

Location

Headquarters

HQ city
Brooklyn
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Fisher Wallace Laboratories business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Prescription Wearable Device Sales: Sale of FDA-cleared brain stimulation devices directly to patients with prescriptions. The company has sold over 70,000 units of its proof-of-concept device.
  2. Accessories and Consumables: Sale of replacement accessories including sponges, headbands, lead wires, and carrying cases for the Version 1.0 device.
  3. Equity Crowdfunding: SEC-regulated equity crowdfunding campaigns raising capital from early adopters and retail investors. Over $11 million raised collectively through these campaigns.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAccessories and replacement parts for Version 1.0 device

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Fisher Wallace Laboratories product offering

Product offering

Core offering

Fisher Wallace Laboratories designs, manufactures, and sells prescription wearable brain stimulation devices using Transcranial Alternating Current Stimulation (tACS) for the treatment of anxiety, depression, and insomnia. Its currently commercial device, Version 1.0, is FDA-cleared, with over 70,000 units sold; the next-generation OAK device is in development pending initial FDA clearance anticipated in Q3 2026. The company also sells replacement accessories — sponges, headbands, lead wires, receptacles, and carrying cases — to support its installed base.

Product overview

Fisher Wallace Laboratories offers prescription wearable brain stimulation devices for treating neuropsychiatric disorders. The portfolio consists of two main products: the original Version 1.0 proof-of-concept device (FDA-cleared for anxiety, depression, and insomnia, with over 70,000 units sold since 2010) and the next-generation OAK device (anticipating FDA clearance in Q3 2026). Both products use Transcranial Alternating Current Stimulation (tACS) technology. The product line is supported by a range of accessories including replacement sponges, headbands, lead wires, electrode receptacles, and carrying cases.

Differentiator

Problem solved

Functional benefit

Brands

  • OAK: Next-generation prescription brain stimulation device designed for population-scale, the result of 17 years of clinical research and product development in collaboration with the team behind Beats and Nest. Anticipated initial FDA clearance for anxiety treatment in Q3 2026.
  • Version 1.0

Products and services

  • OAK Brain Stimulation Device Prescription wearable brain stimulation device using Transcranial Alternating Current Stimulation (tACS) to treat anxiety at population scale, with anticipated FDA clearance for anxiety in Q3 2026 and follow-on indications for insomnia, depression, and human performance in 2027.
  • Fisher Wallace Version 1.0 Brain Stimulation Device FDA-cleared wearable brain stimulation device using Transcranial Alternating Current Stimulation (tACS) to treat anxiety, depression, and insomnia in adults, distributed to more than 70,000 patients through a prescriber channel.
  • Extra Fisher Wallace Sponges (48 pack) Replacement electrode sponges packaged in a 48-count supply (approximately 6 months) intended for Version 1.0 device users, with recommended replacement every two weeks.
  • Replacement Velcro Headband Adjustable replacement Velcro headband used to secure electrode placement during Version 1.0 brain stimulation treatment sessions.
  • Replacement Black Lead Wire Replacement black lead wire that connects the Version 1.0 brain stimulation device to the headband electrodes.
  • Replacement Red Lead Wire Replacement red lead wire that connects the Version 1.0 brain stimulation device to the headband electrodes.
  • Replacement Sponge Receptacles Replacement electrode receptacles that hold sponges on the Version 1.0 brain stimulation device during treatment sessions.
  • Fisher Wallace Pouch Carry case designed for storing and transporting the Fisher Wallace brain stimulation device and its accessories.

Quantifiable outcome

  • Rapid anxiety symptom reduction that continued improving over eight-week study period in 164 first responders
  • +3 more outcomes

Companies that use Fisher Wallace Laboratories

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Fisher Wallace Laboratories technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Fisher Wallace Laboratories partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • Harvard Medical SchoolmajorStrategic or Co-development PartnerResearchers at Harvard Medical School modeled the strength of the company's neurostimulation in the brain, demonstrating significant engagement of structures governing mood, sleep, autonomic function, and cognitive resilience in 2025 research.
  • Massachusetts General HospitalmajorStrategic or Co-development PartnerCollaborated with Fisher Wallace on clinical research demonstrating device effectiveness and safety. Home to key advisor Maurizio Fava, MD, Chair of Department of Psychiatry at Mass General Brigham.
  • U.S. Department of Veterans AffairsmajorStrategic or Co-development PartnerCompany's next-generation technology OAK is currently being pilot tested in the U.S. Department of Veterans Affairs. Advisory board includes Ninth Secretary of Veterans Affairs David Shulkin.
  • Seattle Police DepartmentcoreStrategic or Co-development PartnerCollaborated in real-world study of 164 first responders demonstrating rapid anxiety symptom reduction over eight-week study period as part of FDA clearance application.
  • Washington State UniversitycoreStrategic or Co-development PartnerPartnered with company and other first responder organizations for the clinical study supporting FDA clearance application.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Fisher Wallace Laboratories competitors and assessment

Company assessment

Direct peers

  • Alpha-Stim (Electromedical Products): Alpha-Stim manufactures FDA-cleared cranial electrotherapy stimulation (CES) devices for anxiety, insomnia, and depression. It is the most direct competitor to Fisher Wallace in non-invasive electrotherapeutic brain stimulation for mental health, serving overlapping patient populations and prescriber channels.
  • Neuronetics: Neuronetics markets NeuroStar, a transcranial magnetic stimulation (TMS) system for major depressive disorder. It competes for the same prescriber relationships and depression patient population as Fisher Wallace, offering an alternative non-invasive brain stimulation modality.
  • Brainsway: Brainsway develops deep transcranial magnetic stimulation (Deep TMS) systems for depression, OCD, and other psychiatric conditions. It is a comparable non-pharmaceutical, non-invasive neuromodulation company serving similar patient populations and prescriber markets as Fisher Wallace.
  • NeuroSigma: NeuroSigma markets the Monarch eTNS system, a non-invasive external trigeminal nerve stimulation device cleared by FDA for ADHD and depression. It is a direct competitor in the prescription non-invasive brain stimulation category targeting neuropsychiatric conditions.

Broad incumbents

  • Magstim: Magstim is an established manufacturer of TMS stimulators and coils used in clinical research and depression treatment. It serves the same transcranial stimulation clinical and research market as Fisher Wallace, with a broader neurology-focused product portfolio.

Emerging players

  • Apollo Neuroscience: Apollo Neuroscience offers a consumer wearable that delivers gentle vibrations to influence the nervous system for stress, sleep, and focus. While it uses a different mechanism (vibrotactile vs. electrical stimulation), it competes for the same mental wellness consumer and prescriber attention.
  • Halo Neuroscience: Halo Neuroscience developed transcranial direct current stimulation (tDCS) headbands initially for athletic performance. It is an emerging non-invasive neurostimulation company with overlapping technology category (electrical brain stimulation) and partial overlap in mental performance applications.
  • Cerebral: Cerebral is a tele-mental-health company prescribing and managing treatment for anxiety, depression, and insomnia. It represents a partial overlap through shared patient population and prescriber relationships, though Cerebral focuses on pharmaceutical rather than device-based treatment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Fisher Wallace Laboratories social profiles

Digital presence

Fisher Wallace Laboratories compliance and trust

Trust signal

Compliance1 record

Fisher Wallace Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fisher Wallace Laboratories leadership team

Management profile

Number of profiles

Profiles5 records

Fisher Wallace Laboratories funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fisher Wallace Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fisher Wallace Laboratories

What does Fisher Wallace Laboratories do?

Fisher Wallace Laboratories designs, manufactures, and sells prescription wearable brain stimulation devices using Transcranial Alternating Current Stimulation (tACS) for the treatment of anxiety, depression, and insomnia. Its currently commercial device, Version 1.0, is FDA-cleared, with over 70,000 units sold; the next-generation OAK device is in development pending initial FDA clearance anticipated in Q3 2026. The company also sells replacement accessories — sponges, headbands, lead wires, receptacles, and carrying cases — to support its installed base.

Is Fisher Wallace Laboratories a public or private company?

Fisher Wallace Laboratories is a private company. It is classified as venture growth investor backed and is currently operating.

When was Fisher Wallace Laboratories founded?

Fisher Wallace Laboratories was founded in 2009. It employs 1 to 10 people.

Where is Fisher Wallace Laboratories based?

Fisher Wallace Laboratories is headquartered in Brooklyn, United States, in the North America region.

How does Fisher Wallace Laboratories make money?

Three revenue lines are on record. Prescription Wearable Device Sales are the primary driver. The others are accessories and Consumables and equity Crowdfunding.

Who are Fisher Wallace Laboratories's main competitors?

Direct peers on record are Alpha-Stim (Electromedical Products), Neuronetics, Brainsway and NeuroSigma. Magstim is listed as a broad incumbent. Emerging players are Apollo Neuroscience, Halo Neuroscience and Cerebral.

Does Fisher Wallace Laboratories have an API?

No public API is recorded for Fisher Wallace Laboratories.

What industry is Fisher Wallace Laboratories in?

Fisher Wallace Laboratories's product category is Wearable Neurostimulation Devices. Its primary akta.pro industry code is CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices), with a secondary code of CRACAIAG, Sleep Tech Wearables. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FisherwallaceInvest in Fisher Wallace – The Bright Future of Mental HealthcareFisher Wallace Laboratories has submitted an application to the FDA for clearance of its OAK device, with approval expected by the end of Summer 2026. The company is simultaneously partnering with Maclean Health to distribute its technology to the U.S. Department of Veterans Affairs and is conducting a Regulation CF equity crowdfunding campaign to raise capital.Today on MedscapeNoninvasive Brain Stimulation Shows Rapid Relief for MDDA randomized, sham-controlled trial indicates that noninvasive transcranial alternating current stimulation (tACS) using the OAK device from Fisher Wallace Laboratories provides rapid relief for major depressive disorder, particularly in women with high treatment adherence. Although initial primary efficacy outcomes showed no significant difference between active and sham groups, post hoc analyses revealed superior improvement for the active tACS group, prompting plans for a longer study to seek FDA approval. Independent experts describe the findings as promising but preliminary, emphasizing the need for replication in larger studies with clinician-adminrated ratings to confirm efficacy beyond placebo effects.MediumMediumThis article is an interview with Kelly Roman, Co-Founder and CEO of Fisher Wallace Labs, discussing how their prescription wearable technology impacts overall wellness. The text highlights the company's role as a market leader in this specific medical niche and its engagement with customers through equity crowdfunding.StartEngineInvest in Fisher Wallace LaboratoriesFisher Wallace Laboratories is raising capital to fund the development and FDA approval of its Version 2.0 wearable medical device for treating psychiatric disorders. The company, which has generated over $30 million in lifetime revenue from its initial device, aims to disrupt the mental health industry by offering an affordable, prescription-only treatment option via telemedicine.GlobeNewswireSeattle Police Department Partners With Fisher Wallace to Improve Officer WellnessThe Seattle Police Department announced a partnership with Fisher Wallace to support officer mental health, with Washington State University as clinical lead. The pilot study aims to identify treatment solutions for on-the-job stress, as officers face higher risks of depression, anxiety, and PTSD.The Healthcare Technology Report.Fisher Wallace Wearable Technology Treats Depression, Anxiety, And InsomniaFisher Wallace Laboratories received FDA clearance for its wearable brain stimulator, a device that uses pulsed electrical currents to treat depression, anxiety, and insomnia. The company recently raised millions through equity crowdfunding on StartEngine and has submitted results from three clinical trials to support the approval. This development offers a non-pharmaceutical alternative to traditional medications amid rising mental health issues in the US.MassDeviceThe medical device startup that is disrupting Big PharmaFisher Wallace Laboratories, a medical device startup, has raised millions via equity crowdfunding on StartEngine to fund FDA-cleared wearable brain stimulation technology for treating depression, anxiety, and insomnia. The company deployed over $2 million from its StartEngine campaign to conduct three clinical trials during the pandemic, submitting results to the FDA on March 19, 2021 for new approval and re-clearance to treat MDD, GAD, and insomnia. The CEO envisions a future where drug therapy becomes a last resort for mental health, positioning the device as a more affordable alternative with fewer side effects than traditional pharmaceuticals.ADDitude3 Digital Therapies That Treat ADHD Without MedicationThe article profiles three digital therapies for treating ADHD without medication: Akili Interactive's prescription video game AKL-T01, Fisher Wallace Laboratories' cranial electrotherapy stimulator, and the FDA-cleared Monarch eTNS system. These technologies utilize brain stimulation or neurofeedback to reduce symptoms such as inattention and impulsivity, with clinical studies supporting their efficacy. The FDA recently cleared the Monarch device for pediatric ADHD, marking a significant regulatory milestone for non-pharmacological treatments.Digital TrendsDial 1 for euphoria: What happens when we can zap our brains into any mood?The article discusses the emerging technology of electrotherapy stimulation as a low-cost, prescription-based alternative to pharmaceutical treatments for mental health conditions like depression and anxiety. It highlights Fisher Wallace as a leading provider of FDA-approved devices while noting that clinical research at Mt. Sinai Beth Israel has demonstrated their efficacy with zero side effects. The piece also explores the broader ethical implications and potential societal impacts of widespread access to mood-altering brain stimulation technologies.Forbes4 Technologies Innovating Mental Health In 2016Four mental health technology companies are highlighted for 2016: Pacifica, pala-linq, Spire, and Fisher Wallace Stimulator. Pacifica is a self-help app for anxiety, pala-linq tracks recovery for substance abuse, Spire detects mood via wearable, and the Fisher Wallace Stimulator is an FDA-approved neurostimulation device for depression and anxiety.